



PRIMARY CARE PERSPECTIVES ON ALZHEIMER'S DISEASE

Adaptive Strategies to Improve Cognitive Assessment, Promote Earlier Diagnosis, and Optimize Care



March 23, 2023

West Virginia Academy of Family Physicians
Charleston, WV

ceCONCEPTS 
HEALTHCARE EDUCATION

Presented by Creative Educational Concepts, LLC.
Supported by an independent educational grant from Genentech.

ACTIVITY OVERVIEW

This AAFP-accredited educational series will focus on content tailored to the sentinel role of the primary care clinician on the Alzheimer's disease treatment team. Particular emphasis will be on symptom recognition, evidence-supported screening protocols and biomarker-based disease characterization, timely and accurate diagnosis, and shared decision making. Further, this series will focus on multidisciplinary and interprofessional referral strategies that will equip and empower the primary care team with the knowledge and confidence to optimize patient outcomes across the disease continuum.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Review the etiology, epidemiology, and multifaceted pathophysiology of Alzheimer's disease (AD), highlighting pathologic processes that may manifest years before symptom onset.
 - Discuss the paramount importance of symptom recognition and routine screening protocols to identify mild cognitive impairment (MCI) and promote early AD diagnosis.
 - Evaluate currently-available cognitive assessment tools, with an emphasis on those best suited for the primary care setting, and summarize expert consensus AD diagnostic criteria across the disease continuum.
 - Examine how biomarker-driven disease characterization, including blood-based metrics, supports timely and accurate AD diagnosis and treatment initiation.
 - Use real-world cases from the primary care perspective to design evidence-supported and patient-centric diagnostic plans that incorporate shared decision making and multidisciplinary and interprofessional referrals.
-

TARGET AUDIENCE

This educational initiative is targeted to primary care physicians and their interprofessional care team of nurse practitioners, and physician assistants.

AGENDA

8:00-8:10 AM	Welcome and Introductions/Pre-test
8:10-8:20 AM	Fundamental Facets of Alzheimer's Disease: Epidemiology, Pathophysiology, and the Critical Need for Early Diagnosis
8:20-8:40 AM	Recognizing Early Cognitive Decline: Principal Pillars of Cognitive Assessment in the Primary Care Setting
8:40-8:55 AM	Fortifying the Frontline: The Sentinel Role of the Primary Care Clinician on the Comprehensive Care Team
8:55-9:00 AM	Conversations with the Expert/Audience Q&A/Post-test

FACULTY



Gregory A. Jicha, MD, PhD

Professor of Neurology

Robert T. & Nyles Y. McCowan Endowed Chair in Alzheimer's Disease

Sanders-Brown Center on Aging

University of Kentucky Alzheimer's Disease Center

Lexington, KY

ACCREDITATION



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The AAFP has reviewed Primary Care Perspectives on Alzheimer's Disease: Adaptive Strategies to Improve Cognitive Assessment, Promote Earlier Diagnosis, and Optimize Care, and deemed it acceptable for AAFP credit. Term of approval is from 02/15/2023 to 06/30/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE INFORMATION

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers' bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Presenters

Gregory A. Jicha, MD, PhD-has disclosed that he receives research support from Cassava, Cycleron, Eisai, Lilly, Neurovision, NovoNordisk, and Vivoryon.

Mark Huffmyer, PharmD, BCGP, BCACP-has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer

Jennifer Gholson, MD-has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff

Erin Spencer, PharmD-has no relevant financial relationships to disclose in relation to the content of this activity.

Ashley C. Lilly, MHA-has no relevant financial relationships to disclose in relation to the content of this activity.

BIBLIOGRAPHY AND SUGGESTED READING

- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):270-279.
- Alzheimer's Association. 2010 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2010;6(2):158-194.
- Alzheimer's Association. 2022 Alzheimer's disease facts and figures. Alzheimer's Association website. <https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf>. Accessed October 2022.
- Alzheimer's Disease International. World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost, and trends. ADI website. <http://www.alz.co.uk/research/world-report-2015>. Accessed October 2022.
- Alzheimer's Disease International. World Alzheimer report 2019: attitudes to dementia. ADI website. <https://www.alzint.org/u/WorldAlzheimerReport2019.pdf>. Accessed October 2022.
- American Academy of Neurology (AAN). Practice guideline update: mild cognitive impairment (MCI). December 27, 2017. AAN website. <https://www.aan.com/Guidelines/Home/GetGuidelineContent/882>. Accessed October 2022.
- Atri A. Current and Future Treatments in Alzheimer's Disease. *Semin Neurol*. 2019;39(2):227-240.
- Atri A. Effective pharmacological management of Alzheimer's disease. *Am J Manag Care*. 2011;17(Suppl 13):S346-S355.
- Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. *Med Clin North Am*. 2019;103(2):263-293.
- Atri A, Hendrix J, Carrillo MC, et al. Alzheimer's Association best clinical practice guidelines for the evaluation of neurodegenerative cognitive behavioral syndromes: Alzheimer's disease and dementias in the United States. Presented at: Alzheimer's Association International Conference; July 22-26, 2018; Chicago, Illinois.
- Bateman RJ, Blennow K, Doody R, et al. Plasma biomarkers of AD emerging as essential tools for drug development: an EU/US CTAD task force report. *J Prev Alzheimers Dis*. 2019;6(3):169-173.
- Bateman RJ, Xiong C, Benzinger TL, et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease [published correction appears in: *N Engl J Med*. 2012;367(8):780]. *N Engl J Med*. 2012;367(9):795-804.
- Benedet AL, Ashton NJ, Pascoal TA, et al. Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. *Alzheimers Dement (Amst)*. 2019;11:679-689.
- Blennow K. A review of fluid biomarkers for Alzheimer's disease: moving from CSF to blood. *Neural Ther*. 2017;6(Suppl 1):15-24.
- Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. *J Intern Med*. 2018;284(6):643-663.
- Borson S, Scanlan J, Brush M, et al. The mini-cog: a cognitive "vital signs" measure for dementia screening in multi-lingual elderly. *Int J Geriatr Psychiatry*. 2000;15(11):1021-1027.
- Brejijyh Z, Karaman R. Comprehensive review on Alzheimer's disease: causes and treatment. *Molecules*. 2020;25(24):5789.
- Cordell CB, Borson S, Boustani M, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare annual wellness visit in a primary care setting. *Alzheimers Dement*. 2013;9(2):141-150.
- Cummings J, Aisen P, Lemere C, et al. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. *Alzheimers Res Ther*. 2021;13(1):98.
- Cummings J, Fox N. Defining disease modifying therapy for Alzheimer's disease. *J Prev Alzheimers Dis*. 2017;4(2):109-115.
- Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. *Alzheimers Dement (N Y)*. 2021;7(1):e12179.
- Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer's disease: what, when, and why? *Ann Clin Transl Neurol*. 2015;2(3):307-323.
- de Castro AKA, Pinheiro PR, Pinheiro MCD, et al. Towards the applied hybrid model in decision making: a neuropsychological diagnosis of Alzheimer's disease study case. *Int J Comput Intell Sys*. 2011;4:89-99.
- Dickerson BC, Atri A (eds). *Dementia: Comprehensive Principles and Practice*. New York, New York: Oxford University Press; 2014.
- Does obesity increase dementia risk? Cognitive Vitality website. <https://www.alzdiscovery.org/cognitive-vitality/blog/does-obesity-increase-dementia-risk#:~:text=People%20who%20have%20a%20high%20BMI%20and%20central,developing%20dementia%20than%20people%20without%20excess%20belly%20fat>. Accessed October 2022.
- Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. *Nat Rev Neurol*. 2017;13(8):457-476.
- Fisher Center for Alzheimer's Research Foundation. <https://www.alzinfo.org/understand-alzheimers/alzheimers-disease-facts-and-statistics/#:~:text=Alzheimer%E2%80%99s%20disease%20kills%20more%20people%20every%20year%20than,breast%20cancer%2C%2Doprostate%20cancer%20and%20essential%20hypertension%20combined>. Accessed October 2022.
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198.
- Galvin JE, Aisen P, Langbaum JB, et al. Early stages of Alzheimer's disease: evolving the care team for optimal patient management. *Front Neurol*. 2021;11:592302.
- GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2019;18(1):88-106.
- Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. *J Nutr Health Aging*. 2006;10(5):417-429.
- Getsios D, Blume S, Ishak KJ, et al. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. *Alzheimers Dement*. 2012;8(1):22-30.
- Grossberg GT, Tong G, Burke AD, Tariot PN. Present algorithms and future treatments for Alzheimer's disease. *J Alzheimers Dis*. 2019;67(4):1157-1171.
- Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. *Nat Rev Drug Discov*. 2010;9(7):560-574.
- Hansson O. Biomarkers for neurodegenerative diseases. *Nat Med*. 2021;27(6):954-963.
- Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States. *N Engl J Med*. 2013;368(14):1326-1334.
- Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. *Arch Neurol*. 2011;68(8):1062-1064.
- Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. *Alzheimers Dement*. 2011;7(4):474-485.e4.
- Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562.
- Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol*. 2010;9(1):119-128.
- James BD, Leurgans SE, Hebert LE, et al. Contribution of Alzheimer disease to mortality in the United States. *Neurology*. 2014;82(12):1045-1050.
- Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. *Lancet Neurol*. 2020;19(3):271-278.

- Julayanont P, Brousseau M, Chertkow H, et al. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. *J Am Geriatr Soc*. 2014;62(4):679-684.
- Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement (N Y)*. 2018;4:575-590.
- Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. *Nat Rev Dis Primers*. 2021;7:33.
- Kolanko MA, Win Z, Loreto F, et al. Amyloid PET imaging in clinical practice. *Pract Neurol*. 2020;20(6):451-462.
- Lashley T, Schott JM, Weston P, et al. Molecular biomarkers of Alzheimer's disease: progress and prospects. *Dis Model Mech*. 2018;1(5):dmm031781.
- Lee CM, Woodward M, Batty GD, et al. Association of anthropometry and weight change with risk of dementia and its major subtypes: a meta-analysis consisting 2.8 million adults with 57,294 cases of dementia. *Obes Rev*. 2020;21:e12989.
- Liss JL, Seleri Assunção S, Cummings J, et al. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. *J Intern Med*. 2021;290(2):310-334.
- Liu JL, Hlavka JP, Hillestad R, et al. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer's treatment. 2017. RAND Corporation website. https://www.rand.org/pubs/research_reports/RR2272.html. Accessed October 2022.
- Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396(10248):413-446.
- Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-2734.
- Matte S, Cho SK, Bittner T, et al. Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times. *Alzheimers Dement (Amst)*. 2020;12(1):e12081.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):263-269.
- Meyerhoff DJ, MacKay S, Constans JM, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. *Ann Neurol*. 1994;36(1):40-47.
- Milne A, Culverwell A, Guss R, et al. Screening for dementia in primary care: a review of the use, efficacy, and quality of measures. *Int Psychogeriatr*. 2008;20(5):911-926.
- Molinuevo JL, Ayton S, Batrla R, et al. Current state of Alzheimer's fluid biomarkers. *Acta Neuropathol*. 2018;136(6):821-853.
- Morhardt D, Weintraub S, Khayum B, et al. The CARE pathway model for dementia: psychosocial and rehabilitative strategies for care in young-onset dementias. *Psychiatr Clin North Am*. 2015;38(2):333-352.
- Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment [published correction appears in: *J Am Geriatr Soc*. 2019;67(9):1991]. *J Am Geriatr Soc*. 2005;53(4):695-699.
- National Institute for Health and Care Excellence (NICE). Dementia: assessment, management, and support for people living with dementia and their carers. NICE website. <https://www.nice.org.uk/guidance/ng97/chapter/Recommendations>. Accessed October 2022.
- Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. *Neurology*. 2018;90(3):126-135.
- Pinheiro L, Faustino C. Therapeutic strategies targeting amyloid- β in Alzheimer's disease. *Curr Alzheimer Res*. 2019;16(5):418-452.
- Porsteinsson AP, Isaacson RS, Knox S, et al. Diagnosis of early Alzheimer's disease: clinical practice in 2021. *J Prev Alzheimers Dis*. 2021;8(3):371-386.
- Rasmussen J, Langerman H. Alzheimer's disease—why we need early diagnosis. *Degener Neurol Neuromuscul Dis*. 2019;9:123-130.
- Robert P, Ferris S, Gauthier S, et al. Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? *Alzheimers Res Ther*. 2010;2(4):24.
- Shaughnessy L, Sheard S, Goldfarb D, Atri A. Cognitive assessment of Alzheimer's disease and dementias in clinical practice: pragmatics of brief instruments and neuropsychological evaluation. *J Clin Psychiatry*. 2019;80(4):MS18002BR2C.
- Sheehan B. Assessment scales in dementia. *Ther Adv Neurol Disord*. 2012;5(6):349-358.
- Sheppard O, Coleman M. Alzheimer's disease: etiology, neuropathology and pathogenesis. In: Huang X, editor. *Alzheimer's Disease: Drug Discovery* [Internet]. Brisbane, Australia: Exon Publications; December 18, 2020: Chapter 1.
- Strand HB, Wills AK, Langballe EM, et al. Weight change in midlife and risk of mortality from dementia up to 35 years later. *J Gerontol Med Sci*. 2017;72(6):855-860.
- Tarawneh R. Biomarkers: our path towards a cure for Alzheimer disease. *Biomark Insights*. 2020;15:1177271920976367.
- Tariq SH, Tumosa N, Chibnall JT, et al. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—a pilot study. *Am J Geriatr Psychiatry*. 2006;14(11):900-910.
- Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol*. 2022;21(1):66-77.
- Tinetti ME, McAvay GJ, Murphy TE, et al. Contribution of individual diseases to death in older adults with multiple diseases. *J Am Geriatr Soc*. 2012;60(8):1448-1456.
- United Nations. World population prospects: key findings and advance tables. 2015 revision. United Nations website. https://esa.un.org/unpd/wpp/publications/files/key_findings_wpp_2015.pdf. Accessed October 2022.
- Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. *Nat Rev Drug Discov*. 2006;5(11):956-70.
- Vespa J. The graying of America: more older adults than kids by 2035: the U.S. joins other countries with large aging populations. March 13, 2018. U.S. Census Bureau website. <https://www.census.gov/library/stories/2018/03/graying-america.html>. Accessed October 2022.
- Weimer DL, Sager MA. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes. *Alzheimers Dement*. 2009;5(3):215-226.
- Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. *Lancet Neurol*. 2016;15(5):455-532.
- Wong W. Economic burden of Alzheimer disease and managed care considerations. *Am J Manag Care*. 2020;26(8 Suppl):S177-S183. doi:10.37765/ajmc.2020.88482.
- Yokomizo JE, Simon SS, Bottino CM. Cognitive screening for dementia in primary care: a systematic review. *Int Psychogeriatr*. 2014;26(11):1783-1804.
- Young-onset Alzheimer's. Mayo Clinic website. <https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048356>. Accessed October 2022.
- Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies. *Mol Psychiatry*. 2021;26(1):296-308.
- Zissimopoulos J, Crimmins E, St. Clair P. The value of delaying Alzheimer's disease onset. *Forum Health Econ Policy*. 2014;18(1):25-39.
- Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci*. 2011;12(12):723-738.



Creative Educational Concepts, LLC

PO Box 55230

Lexington, KY 40555

859-260-1717

ceconcepts.com

Questions about this activity?

Email info@ceconcepts.com